Cancer:精准医疗中,骨活组织检查在晚期前列腺癌中的分析

2017-12-26 AlexYang MedSci原创

转移性活组织检查在患有晚期前列腺癌病人中越来越流行,主要目的是搜寻起作用的靶标和/或者鉴定出现的抗性机制。由于骨转移和它们硬化性质,获得足够的组织用来临床和基因组研究仍具有挑战。研究人员在2013年2月和2017年3月之间,募集了患有前列腺癌骨转移的病人,从而进行前瞻性的成像阴道的骨组织活检。研究人员搜集了新鲜的骨组织和血凝块。密质骨用添加了脱钙剂的福尔马林浸泡,进一步用于诊断。骨髓和血凝块在最优

转移性活组织检查在患有晚期前列腺癌病人中越来越流行,主要目的是搜寻起作用的靶标和/或者鉴定出现的抗性机制。由于骨转移和它们硬化性质,获得足够的组织用来临床和基因组研究仍具有挑战。

研究人员在2013年2月和2017年3月之间,募集了患有前列腺癌骨转移的病人,从而进行前瞻性的成像阴道的骨组织活检。研究人员搜集了新鲜的骨组织和血凝块。密质骨用添加了脱钙剂的福尔马林浸泡,进一步用于诊断。骨髓和血凝块在最优的切片温度下冷冻,并用来进行二代测序。另外,研究人员还从最优切片温度模具上获得了冷冻切片,用来进行肿瘤组织学和纯度鉴定。研究人员还对组织进行了破碎,用来进行DNA和RNA提取以及进行全外显子组测序和RNA测序。

研究分析了来自64名病人的70份骨活组织检查。能够确定前列腺癌的诊断材料数量为60(85.7%)。DNA和RNA产量的平均水平分别为25.5ng/μL和16.2ng/μL。全外显子组测序在49(81.7%)个材料中成功的进行,另外,在20(33.3%)个材料中进行了RNA测序。复发性变异与预测一致,包括了AR、PTEN、TP53、BRCA2和SPOP基因。最后,研究人员指出,他们的前列腺癌骨组织活检方法保证了高质量的DNA和RNA用来进行测序,并且在骨转移病人中,也许可以用来鉴定和分析起作用的变异和相关的抗性机制。

原始出处:

Sailer V, Schiffman MH, Kossai M et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 19 Dec 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953496, encodeId=ad9b1953496e0, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Thu Oct 04 15:24:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083220, encodeId=04042083220b5, content=<a href='/topic/show?id=ce946525058' target=_blank style='color:#2F92EE;'>#活组织检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65250, encryptionId=ce946525058, topicName=活组织检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Sat Apr 07 09:24:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403274, encodeId=15b414032e465, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Thu Dec 28 11:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412775, encodeId=d8a41412e7527, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Thu Dec 28 11:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953496, encodeId=ad9b1953496e0, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Thu Oct 04 15:24:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083220, encodeId=04042083220b5, content=<a href='/topic/show?id=ce946525058' target=_blank style='color:#2F92EE;'>#活组织检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65250, encryptionId=ce946525058, topicName=活组织检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Sat Apr 07 09:24:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403274, encodeId=15b414032e465, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Thu Dec 28 11:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412775, encodeId=d8a41412e7527, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Thu Dec 28 11:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953496, encodeId=ad9b1953496e0, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Thu Oct 04 15:24:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083220, encodeId=04042083220b5, content=<a href='/topic/show?id=ce946525058' target=_blank style='color:#2F92EE;'>#活组织检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65250, encryptionId=ce946525058, topicName=活组织检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Sat Apr 07 09:24:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403274, encodeId=15b414032e465, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Thu Dec 28 11:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412775, encodeId=d8a41412e7527, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Thu Dec 28 11:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1953496, encodeId=ad9b1953496e0, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Thu Oct 04 15:24:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083220, encodeId=04042083220b5, content=<a href='/topic/show?id=ce946525058' target=_blank style='color:#2F92EE;'>#活组织检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65250, encryptionId=ce946525058, topicName=活组织检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Sat Apr 07 09:24:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403274, encodeId=15b414032e465, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Thu Dec 28 11:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412775, encodeId=d8a41412e7527, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Thu Dec 28 11:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=)]

相关资讯

EUR J CANCER:多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验:RECARDO试验

多西紫杉醇(Docetaxel)作为一种转移性去势难治性前列腺癌(mCRPC)的一线治疗药物,目前还没有一项前瞻性随机对照试验对其进行详细研究。近日荷兰学者便进行了一项这样的临床试验,他们对既往接受过多西紫杉醇治疗的前列腺癌患者继续使用多西紫杉醇及多西紫杉醇联合卡铂治疗。

2017 EANM指南:转移性去势难治性前列腺癌应用镭-233放射治疗

2017年12月,欧洲核医学协会(EANM)发布了转移性去势难治性前列腺癌应用镭-233放射治疗指南。指南主要目的是为核医学专家在评估应用镭-233放射治疗以及放射治疗期间的患者管理提供指导建议。

Sci Rep:低风险局部前列腺癌的筋膜内和非筋膜内根治性前列腺切除术治疗效果比较

最近,有研究人员在元分析研究中,比较了筋膜内根治性前列腺切除术(IFRP)和非筋膜内根治性前列腺切除术(NIFRP)在患有低风险前列腺癌患者中治疗的结果,主要结果在肿瘤方面和功能性方面。研究人员通过在PubMed、EMBASE、Cochrane Library、Ovid和ISI Web知识数据库中的搜索,鉴定了相关的文章。他们的研究包括了来自7个符合条件研究的2096名病人。这些混合数据展示了肿瘤

J Clin Oncol:遗传学检测在遗传性前列腺癌风险评估中的作用

在美国费城召开了2017前列腺癌共识会议,主要着眼于前列腺癌遗传风险检测以及遗传咨询、筛查、根据遗传学检测结果如何治疗等问题。

J Biol Chem:研究发现前列腺癌治疗新靶点!

吉非替尼药物通过抑制表皮生长因子受体(EGFR)信号传导来治疗乳腺癌,肺癌和其他癌症,但对前列腺癌的作用有限。存在于细胞膜上的EGFR参与细胞增殖和真皮,肺和消化组织的发育。当突变导致其过度激活时,可导致细胞增殖和肿瘤形成增加。

JCO:7个月PSA水平是转移性激素敏感前列腺癌的预后因素

JCO近期发表了一篇文章,研究一项比较去势治疗(ADT)单独或联合多西他赛治疗激素敏感前列腺癌前瞻性临床试验中PSA水平与患者总生存之间的关系。